Watch past educational presentations and see live events in real time
Reference our medication guides for helpful information
Make a choice that matters
The best care starts with the best information
Registration is open for the Division Directors and Program Directors Conference March 8 - 9, 2019.
Looking for rheumatic disease types, treatments, and associated rheumatology definitions? From abatacept to WOMAC, learn about common terms related to arthritis and rheumatic and musculoskeletal diseases. Looking for information about MACRA? See MACRA terms and definitions.
Monoclonal antibody used in the treatment of non-Hodgkin lymphoma. Also used with another medication to treat the symptoms of rheumatoid arthritis in people who have already been treated with a tumor necrosis factor (TNF) inhibitor.
See more >
Brief self-administered questionnaire of disease symptoms for patients with rheumatoid arthritis.
Systemic granulomatous disease of unknown cause, especially involving the lungs with resulting interstitial fibrosis, but also involving the lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.
Autoimmune rheumatic disease affecting the connective tissues of the body. It is sometimes called CREST syndrome. Limited scleroderma affects about half the patients who have systemic scleroderma, while others may have the diffuse, more widespread, and rapidly acting form of this systemic disease. May cause slow-acting hardening of the skin over years, typically on the hands, fingers, and face. It may also affect internal organs, such as the esophagus, gastrointestinal tract, heart, lungs, or kidneys, causing fibrous hardening of tissues. However, limited scleroderma affects internal organs less frequently and severely than the diffuse form of the disease. Patients with limited scleroderma may develop pulmonary hypertension, a narrowing of lung blood vessels that can cause shortness of breath.
Cutaneous lesions characterized by indurated, slightly depressed plaques of thickened dermal fibrosis tissue of a whitish of yellowish-white color surrounded by a pinkish or purplish halo.
Thickening and induration of the skin caused by new collagen formation, with atrophy of pilosebaceous follicles; either a manifestation of progressive systemic sclerosis or localized (morphea).
Class of chemical compounds that selectively, to varying degrees, inhibit the reuptake of serotonin by presynaptic neurons and are posited to exert their antidepressant effect by this mechanism.
General term covering those steroid hormones that are formed by testicular, ovarian, and adrenocortical tissues, and that are androgens or estrogens.
Multi-purpose, short-form health survey with only 36 questions. It yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures and a preference-based health utility index. It is a generic measure, as opposed to one that targets a specific age, disease, or treatment group.
The SDAI is the sum of 5 outcome parameters: tender and swollen joint counts (28 joints assessed), patient’s and physician’s global assessment of disease activity (on a 0–10-cm visual analog scale), and C-reactive protein (CRP; normal <1 mg/dl) level. The range of possible scores is 0–86. The Clinical Disease Activity Index (CDAI) is the same as the SDAI but without the CRP.